Weight-loss and obesity procedures would complement AmSurg’s current gastrointestinal service lines, the article quoted AmSurg CEO Christopher Holden as saying. AmSurg is already in talks with a manufacturer of a device, not yet approved by the FDA, to help enhance weight loss and control diabetes, he said. In addition, the company is negotiating a contract with a consultant to weigh the pros and cons of entering the weight-loss market.
Of Amsurg’s 202 ASCs around the country, 142 are GI centers, including 11 acquired in 2009, according to the Business Journal. Meanwhile the number of gastric bypass surgeries performed each year is mushrooming, with 220,000 bariatric or metabolic procedures performed last year, five times the number of such procedures performed a decade ago, according to the article.
Read the Nashville Business Journal report about AmSurg.
